Read by QxMD icon Read

etanercept serum

Canna Ghia, Shashank Akerkar, Shailaja Sabnis, Urk Rao, Gautam Rambhad
BACKGROUND / OBJECTIVES: Biologic anti-TNFs in India have improved the patient management. Significant proportions of patients lose response over time or do not respond. Possible explanations are suboptimal trough anti-TNFa concentrations or antibodies to anti-TNFs. The aim of this project was to set up and standardize an independent laboratory to test immunogenicity of anti-TNF biologics (infliximab and etanercept). METHODS: Three rheumatologists piloted this project approved by independent ethics committee and carried out in compliance with ICH/GCP guidelines...
September 2016: Journal of the Association of Physicians of India
Bart V J Cuppen, Marzia Rossato, Ruth D E Fritsch-Stork, Arno N Concepcion, Yolande Schenk, Johannes W J Bijlsma, Timothy R D J Radstake, Floris P J G Lafeber
BACKGROUND: In rheumatoid arthritis, prediction of response to TNF-alpha inhibitor (TNFi) treatment would be of clinical value. This study aims to discover miRNAs that predict response and aims to replicate results of two previous studies addressing this topic. METHODS: From the observational BiOCURA cohort, 40 adalimumab- (ADA) and 40 etanercept- (ETN) treated patients were selected to enter the discovery cohort and baseline serum profiling on 758 miRNAs was performed...
2016: Arthritis Research & Therapy
Laida Elberdín, Maria Outeda, Pilar Salvador, Sabela Paradela, Rosa María Fernández-Torres, Raquel Iglesias, Eduardo Fonseca, Isabel Martín
Background In the case of psoriatic patients, only a limited number of studies have related serum biological therapies and antidrug antibodies levels to clinical response. With respect to etanercept, the available evidence has not shown any relationship yet. Objective The aim of this study was to determine if there is any correlation among etanercept serum levels, the presence of anti-etanercept antibodies and clinical response to this treatment in psoriatic patients. Setting A 1500-bed hospital (A Coruña University Hospital Complex)...
October 2016: International Journal of Clinical Pharmacy
Masahito Koiwa, Susumu Goto, Kenji Takahashi, Toshikazu Kamada, Shinro Takai, Hiroshi Nakamura
BACKGROUND: Disease activity of rheumatoid arthritis (RA) is evaluated by composite measures, such as Disease Activity Score (DAS). Recently, much attention has been paid to a neutrophil-lymphocyte (N/L) ratio to evaluate the prognosis and the efficacy of intervention in various diseases. To determine whether the N/L ratio is a prognostic marker or a surrogate marker of response to biologics, this study investigated the N/L ratio in RA patients treated with biological agents. METHODS: The medical records were reviewed of 358 patients with RA in routine care who were treated with infliximab (144 patients), etanercept (120 patients), adalimumab (25 patients), tocilizumab (41 patients), or abatacept (28 patients)...
2016: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
José Inciarte-Mundo, Julio Ramirez, Maria Victoria Hernández, Virginia Ruiz-Esquide, Andrea Cuervo, Sonia Raquel Cabrera-Villalba, Mariona Pascal, Jordi Yagüe, Juan D Cañete, Raimon Sanmarti
BACKGROUND: Serum levels of calprotectin, a major S100 leucocyte protein, are associated with disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients. Higher drug trough serum levels are associated with good response in patients treated with tumour necrosis factor inhibitors (TNFi). Power Doppler ultrasound (PDUS) synovitis is predictive of flare and progression of structural damage in patients in clinical remission. The purpose of this study was to analyse the accuracy of calprotectin and TNFi trough serum levels in detecting PDUS synovitis in RA and PsA patients in clinical remission or with low disease activity who were receiving TNFi...
July 8, 2016: Arthritis Research & Therapy
Sandrine Guis, Philippe Berbis, Delphine Stephan, Daniel Bertin, Florent Amatore, Nathalie Balandraud, Nathalie Lesavre, Sophie Desplat-Jégo
BACKGROUND: TNF weakly inducer of apoptosis (TWEAK) is member of the TNF ligand superfamily. Various data support that TWEAK produced by synovial macrophages may contribute to synovitis observed in psoriatic arthritis (PsoA). In PsoA, anti-TNF therapy has been successful in agreement with the key role of TNF in the pathogenesis and the generation by PsoA patients of anti-TNF autoantibodies referred as "beneficial autoimmunity to pro-inflammatory mediators". However, the role of TNF-alpha in the regulation of TWEAK modulation of inflammation during PsoA remains unknown...
2016: Journal of Translational Medicine
Miguel M De Jesus, Jayson S Santiago, Camille V Trinidad, Melvin E See, Kimberly R Semon, Manuel O Fernandez Jr, Francisco S Chung
Psoriasis is a dermatologic disease of immune origins with no definitive cure. We report the Makati Medical Center experience of utilizing autologous mesenchymal stromal cells (MSCs) for one patient with psoriasis vulgaris (PV) and another with psoriatic arthritis (PA). Patients were educated and gave informed consent, according to the principles of the Helsinki Declaration. The protocol was approved by the Cellular Transplantation Ethics Committee of Makati Medical Center. Autologous MSCs were cultured from lipoaspirate, expanded in a clean room class 100 facility (Cellular Therapeutics Center, Makati Medical Center)...
June 9, 2016: Cell Transplantation
Yong Gil Hwang, Goundappa K Balasubramani, Ilinca D Metes, Marc C Levesque, S Louis Bridges, Larry W Moreland
BACKGROUND: The aim was to compare the effect of etanercept (ETN) and conventional synthetic disease-modifying anti-rheumatic drug (DMARD) therapy on serum amyloid A (SAA) levels and to determine whether SAA reflects rheumatoid arthritis (RA) disease activity better than C-reactive protein (CRP). METHODS: We measured SAA and CRP at baseline, 24, 48, and 102 week follow-up visits in 594 patients participating in the Treatment of early RA (TEAR) study. We used Spearman correlation coefficients (rho) to evaluate the relationship between SAA and CRP and mixed effects models to determine whether ETN and methotrexate (MTX) treatment compared to triple DMARD therapy differentially lowered SAA...
2016: Arthritis Research & Therapy
Rosa Alcobendas, Adriana Rodríguez-Vidal, Dora Pascual-Salcedo, Sara Murias, Agustín Remesal, Cristina Diego, Rosa Merino
April 28, 2016: Clinical and Experimental Rheumatology
Ji S van Bezooijen, Birgit C P Koch, Martijn B A van Doorn, Errol P Prens, Teun van Gelder, Marco W J Schreurs
BACKGROUND: To optimize treatment of inflammatory diseases, interest in the measurement of anti-tumor necrosis factor alpha (anti-TNFα) serum drug concentrations is increasing. Preferably, assays for the detection of these drugs should be compared using the same reference material. In this study, 2 commercially available enzyme-linked immunosorbent assays (ELISAs) and a commercially available bioassay for the determination of anti-TNFα drugs are compared. METHODS: Serum samples from infliximab-, adalimumab-, and etanercept-treated patients, control samples from ustekinumab-treated patients, and healthy donors were obtained...
August 2016: Therapeutic Drug Monitoring
Takeshi Kuroda, Hiroyuki Takeuchi, Yukiko Nozawa, Hiroe Sato, Takeshi Nakatsue, Yoko Wada, Hiroshi Moriyama, Masaaki Nakano, Ichiei Narita
BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is potentially fatal infectious complication in patients with rheumatoid arthritis (RA) during immunosuppressive therapy. Hospital survival due to human immunodeficiency virus-unrelated PCP reaches to 60%. The high mortality rate results from difficulties in establishing an early diagnosis, concurrent use of prophylactic drugs, possible bacterial coinfection. We herein report a case of PCP in RA patients who developed the architectural distortions of lung in spite of combined modality therapy...
2016: BMC Research Notes
Yasar Yildirim, Esma Gulsum Cellad, Ali Veysel Kara, Zülfükar Yilmaz, Ali Kemal Kadiroglu, Mehmet Veysi Bahadir, Mesut Gul, Muzaffer Aydin Ketani, Mehmet Emin Yilmaz
Our aim was to evaluate effect of etanercept on oxidative stress parameters in rats with experimental peritonitis and investigate the availability of etanercept usage in the treatment of peritonitis in the future. Twenty-eight rats were divided into four groups as control (group 1), peritonitis (group 2), peritonitis + cefazolin sodium (group 3), and peritonitis + cefazolin sodium + etanercept (group 4). Peritoneal tissue and blood samples were taken from all of the rats for histopathological and biochemical examination...
2016: Oxidative Medicine and Cellular Longevity
Burak Ersoy, Özge Çevik, Özlem Tuğçe Çilingir
Background Being an inevitable component of free tissue transfer, ischemia-reperfusion injury tends to contribute to flap failure. TNF-α is an important proinflammatory cytokine and a prominent mediator of the ischemia-reperfusion injury. Etanercept, a soluble TNF-α binding protein, has shown anti-inflammatory and anti-apoptotic effects in animal models of renal and myocardial ischemia-reperfusion injury. We have designed an experimental study to investigate the effect of etanercept on myocutaneous ischemia-reperfusion injury on transverse rectus abdominis myocutaneous flap model in rats...
August 2016: Journal of Plastic Surgery and Hand Surgery
H M Walters, N Pan, T J A Lehman, A Adams, G D Kalliolias, Y S Zhu, F Santiago, J Nguyen, L Sitaras, S Cunningham-Rundles, T J Walsh, S S Toussi
The aim of this study was to evaluate prospectively cytokine levels and disease activity in juvenile idiopathic arthritis (JIA) patients treated with and without tumour necrosis factor (TNF)-α inhibitors. TNF-α inhibitor-naive JIA subjects were followed prospectively for 6 months. Cytokine levels of TNF-α, interleukin (IL)-1β, IL-6, IL-8, IL-10 and IL-17 were measured at baseline for JIA subjects and healthy controls (HCs). Cytokine levels were then measured at four time-points after initiation of TNF-α inhibition for anti-TNF-α-treated (anti-TNF) JIA subjects, and at two subsequent time-points for other JIA (non-TNF) subjects...
June 2016: Clinical and Experimental Immunology
Iris Detrez, Els Brouwers, Miet Peeters, Nick Geukens, Kurt de Vlam, Ann Gils
The clinical response in ankylosing spondylitis (AS) patients treated with biologic agents can be influenced by pharmacokinetic variability among and within these patients. Therapeutic drug monitoring is seen as a valuable tool to improve patient care. The aim of this study was to generate a panel of mAbs toward etanercept (ETN) and to determine ETN and anti-ETN concentrations in AS patients. mAbs against ETN (MA-ETN) were generated using hybridoma technology. For quantification of ETN concentrations, a mAb-based TNF-coated ELISA and a mAb/mAb-based sandwich-type ELISA were developed...
March 15, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
José Inciarte-Mundo, Maria Victoria Hernández, Virginia Ruiz-Esquide, Sonia Raquel Cabrera-Villalba, Julio Ramirez, Andrea Cuervo, Mariona Pascal, Jordi Yagüe, Juan D Cañete, Raimon Sanmarti
OBJECTIVE: To compare the accuracy of serum calprotectin and acute-phase reactants (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) in stratifying disease activity in rheumatoid arthritis (RA) patients receiving tumor necrosis factor inhibitors (TNFi), and to correlate calprotectin levels with TNFi trough serum levels. METHODS: We conducted a cross-sectional study of 87 RA patients receiving adalimumab, etanercept (ETN), or infliximab (IFX); 56 psoriatic arthritis (PsA) patients and 40 healthy blood donors were included as controls...
July 2016: Arthritis Care & Research
Peter Tougaard, Kristoffer Alexander Zervides, Søren Skov, Axel Kornerup Hansen, Anders Elm Pedersen
A number of anti-tumor necrosis factor alpha (TNF-α) biologics have been developed in recent years, such as adalimumab, etanercept, and infliximab for the treatment of chronic inflammatory disorders like rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis and several other novel drugs that target TNF-α signaling are still being developed. Indeed, blockade of this pathway seems so important amongst immune-targets that TNF-α targeted therapies will continue to have a significant role in the treatment of chronic inflammation...
February 2016: Immunopharmacology and Immunotoxicology
Robin Kahn, Elisabet Berthold, Birgitta Gullstrand, Tobias Schmidt, Fredrik Kahn, Pierre Geborek, Tore Saxne, Anders A Bengtsson, Bengt Månsson
AIM: The relationship between tumour necrosis factor-alpha (TNF-α) and drug survival had not been studied in juvenile idiopathic arthritis (JIA), and there were no laboratory tests to predict the long-term efficacy of biological drugs for JIA. We studied whether serum levels of TNF-α, free or bound to etanercept, could predict long-term efficacy of etanercept in children with JIA. METHODS: We included 41 biologic-naïve patients with JIA who started treatment with etanercept at Skåne University Hospital between 1999 and 2010...
April 2016: Acta Paediatrica
Roberta Priori, Luca Casadei, Mariacristina Valerio, Rossana Scrivo, Guido Valesini, Cesare Manetti
OBJECTIVE: A considerable proportion of patients with rheumatoid arthritis (RA) do not have a satisfactory response to biological therapies. We investigated the use of metabolomics approach to identify biomarkers able to anticipate the response to biologics in RA patients. METHODS: Due to gender differences in metabolomic profiling, the analysis was restricted to female patients starting etanercept as the first biological treatment and having a minimum of six months' follow-up...
2015: PloS One
Antoine Obry, Julie Hardouin, Thierry Lequerré, Frédérique Jarnier, Olivier Boyer, Patrice Fardellone, Peggy Philippe, Christian Marcelli, Xavier Le Loët, Olivier Vittecoq, Pascal Cosette
OBJECTIVE: The recent growth of innovating biologics has opened fascinating avenues for the management of patients. In rheumatoid arthritis, many biologics are currently available, the choice of which being mostly determined empirically. Importantly, a given biologic may not be active in a fraction of patients and may even provoke side effects. Here, we conducted a comparative proteomics study in attempt to identify a predictive theranostic signature of non-response in patients with rheumatoid arthritis treated by etanercept/methotrexate combination...
2015: Theranostics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"